//Your Connection to the Life Sciences Industry
Connect to IBC:LinkedIn iconTwitter iconFacebook iconBlog iconRSS icon
EmailPrint

Registration

Online Registration is Open!
Register by Friday, March 27 to Save Up to $300!

Download Brochure

Add to Outlook Calendar

Find Another IBC Event

Bioconjugates: From Targets to Therapeutics

CSS

Transitioning Innovation into Viable Therapeutic Candidates

May 18-20, 2015 | Parc 55 Hilton | San Francisco, CA

Alt language

Alternative Language Options:

  • Japanese
  • Korean
  • Taiwanese
  • Chinese

SurveyMonkey

We Want Your Opinion! Help us better understand where the biggest opportunities are to advance cancer therapeutics. » Please share your insights

Agenda

Agenda

  Download the Agenda-at-a-Glance PDF, featuring all 3 co-located events

Monday, May 18, 2015

7:00
Registration and Coffee

8:00
Chairperson's Remarks
Jennifer R. Cochran, Ph.D., Associate Professor of Bioengineering and Chemical Engineering, Stanford University

Keynote Presentations

8:15
Peter Senter, Ph.D.
Potent Antibody Drug Conjugates for Cancer Therapy
Peter Senter, Ph.D., Vice President,Chemistry, Seattle Genetics

8:45
Paul J. Carter, Ph.D.
Bispecific Antibodies - Are We There Yet?
Paul J. Carter, Ph.D., Staff Scientist and Senior Director, Antibody Engineering, Genentech, Inc.

9:15
Andreas Plückthun, Ph.D.
New Engineering and Application Perspectives of Scaffold Proteins
Andreas Plückthun, Ph.D., Director, Department of Biochemistry, University of Zurich, Switzerland

9:45
Networking Refreshment Break in Poster and Exhibit Hall

10:10
Chairperson's Remarks
Alan Wahl, Ph.D., Vice President, Research and Discovery, Ambrx, Inc.

Exploring Novel and Emerging Payloads

10:15
ADCs: Leveraging Shared Learnings to Enable Next Generation Success
Alan C. Rigby, Ph.D., Vice President, ADC Biology, Eli Lilly and Company

10:45
New Payloads for ADCs: Challenges and Advancements
Ravi J. Chari, Ph.D., Executive Director, Chemistry and Biochemistry, ImmunoGen, Inc.

11:15
Tuning the Efficacy of Antibody Drug Conjugates via Site-Selective Conjugation
Alan Wahl, Ph.D., Vice President, Research and Discovery, Ambrx, Inc.

11:45
Technology Workshop Presentations

12:15
Networking Luncheon in Poster and Exhibit Hall

1:25
Chairperson's Remarks
Karyn O'Neil, Ph.D., Senior Director and Venture Leader, Centyrex, Janssen R&D

Advances in Bioconjugate Development and Design

1:30
Centyrin Conjugates for Targeted Delivery
Karyn O'Neil, Ph.D., Senior Director and Venture Leader, Centyrex, Janssen R&D

2:00
Cysteine Arylation Enables Facile and Robust Bioconjugation
Bradley L. Pentelute, Ph.D., Pfizer-Laubach Career Development, Professor, Associate Member, Broad Institute of Harvard and MIT, Member, Center for Environmental Health Sciences MIT, Massachusetts Institute of Technology

2:30
Serum Half-life Extension by Site-specific Conjugation to Albumin's Natural Free Cysteine 34
Mikael Bjerg Caspersen, Ph.D., Senior Professional, Novozymes Biopharma

3:00
Networking Refreshment Break in Poster & Exhibit Hall

Breakthroughs in ADC Discovery and Development

3:30
Making Homogeneous and Site-specific ADCs Directly from mABs in Your Fridge
Sean Hu, Ph.D., Senior Vice President, Dophen BioMed

4:00
A pH-Tunable Linker: The Next Generation Of Versatile Linkers For ADC
Cindy Choy, Post-Doctoral Researcher, Washington State University

4:30
Early Phase Formulation Development of Antibody Drug Conjugates (ADC) and its Intermediate Drug Substance, mAb
Ananda K. Seneviratne, Ph.D., Principal Scientist, Analytical and Formulation Development, Agensys, Inc.

5:00
Networking Cocktail Reception in Poster and Exhibit Hall

6:00
Dinner Discussions
(Additional registration fee required - see registration page for details)
Please join us for this highly interactive 3 hour evening exchange in a roundtable format, which encourages participants to share their experiences and concerns amongst several discussion topics that include:
  • GPCRs, Ion Channels and Other Membrane Targets - The Next Hot Targets! Why? What are the Challenges?
    Moderator: Catherine Hutchings, Ph.D., Antibody Alliance Management & Strategic Partnering, Heptares Therapeutics Ltd., United Kingdom
  • Delivery Approaches for Intracellular Biologics
    Moderator: Paul Watt, Ph.D., Chief Scientific Officer, Phylogica Ltd., Australia
  • Strategies for Plasma Half-Life Extension of Biopharmaceuticals
    Moderator: Arne Skerra, Ph.D., Professor, Chief Scientific Officer, XL-protein GmbH, Germany
  • Non-Antibody Targeting Moieties
    Moderator: Robert Lutz, Ph.D., Vice President, Translational Research and Development, ImmunoGen, Inc.
  • Clinical Translatability of Current ADC Programs: Does Patient Selection/Tailoring Improve Success
    Moderator: Alan C. Rigby, Ph.D., Vice President, ADC Biology, Eli Lilly and Company
  • Site-Specific Conjugation and its Progress Towards Clinical Development
    Moderator: Jagath Reddy Junutula, Ph.D., Vice President, Antibody Discovery & Development, Cellerant Therapeutics, Inc.
  • CRISPR's Influence on Therapeutic Development
    Moderator: Ben Haley, Ph.D., Scientist, Genentech
  • What Technological Breakthroughs will Make a Difference to Cell line Development: Enthusiasm Tempered by Realism
    Moderator: Alan Dickson, Ph.D., Professor of Biotechnology, Director, Centre of Excellence in Biopharmaceuticals, Co-Director, BioProNET, The University of Manchester, United Kingdom
  • Cell Line Authentication
    Moderator: Leonard P. Freedman, Ph.D., President, Global Biological Standards Institute

Tuesday, May 19, 2015

7:30
Coffee

8:00
Chairperson's Remarks
Joseph G. Joyce, Ph.D., Director, Vaccine Process Development, Merck Research Laboratories

Advances in Conjugated Vaccines

8:15
V114: Development of a 15-Valent Pneumococcal Conjugate Vaccine
Joseph G. Joyce, Ph.D., Director, Vaccine Process Development, Merck Research Laboratories

8:45
Development of a Malaria Transmission Blocking Vaccine as a Chemically Conjugated Nanoparticle
David Narum, Head of Process Development, NIH, NIAID

9:15
Dialing in the Molecular Attributes of a Therapeutic Vaccine Through Process Control, Characterization and In Vivo Testing
Justin Sperry, Group Leader, Senior Principal Scientist, Pfizer, Inc.

9:45
Networking Refreshment Break in Poster and Exhibit Hall

10:25
Chairperson's Remarks
Bo Arve, Executive Director, Pfizer, Inc.

Beyond ADCs - Assessing Other Areas for Breakthroughs in Bioconjugates

10:30
Site-Specific Techniques for the Rapid and Efficient Preparation of Nanoparticle Conjugates
Andrew Tsourkas, Ph.D., Associate Professor, Department of Bioengineering, University of Pennsylvania

11:00
Optimizing the Production and Quality Control of an ImmunoPET Clinical Imaging Agent
Herman Gill, Research Associate, Genentech

11:30
Technology Workshop Presentations

12:00
Networking Luncheon in Poster and Exhibit Hall

1:25
Chairperson's Remarks
Dimiter Dimitrov, Ph.D., Senior Investigator, Protein Interactions, National Cancer Institute, NIH

Site-Specific Conjugation Methods and Strategies

1:30
Overcome Key Challenges in Antibody Drug Conjugate Design through the SMARTag Technology Platform
Robyn Barfield, Ph.D., Group Leader, Bioconjugation, Catalent Pharma Solutions

2:00
De-risking ADC Development Through Cell-free Based Rapid Make-test Cycles
Alexander Steiner, M.S., Director, Protein Biochemistry, Sutro

2:30
Site-specific Conjugation Through Carbohydrates
Dimiter Dimitrov, Ph.D., Senior Investigator, Protein Interactions, National Cancer Institute, NIH

3:00
Networking Refreshment Break and Last Chance for Poster and Exhibit Viewing

Next Generation Bioconjugates

Featured Presentation

3:45
Robert Lutz, Ph.D. Clinical Development of ADCs Lessons Learned and Where Do We Go From Here
Robert Lutz, Ph.D., Vice President, Translational Research and Development, ImmunoGen, Inc.

4:15
PEG Alternatives - New Applications of PASylation for Therapeutic Protein Development
Arne Skerra, Ph.D., Professor, Chief Scientific Officer, XL-protein GmbH, Germany

4:45
Close of Tuesday Sessions

5:00
Join Us... Happy Hour @ Pier 39 Overlooking San Francisco Bay
This networking reception is at Players Sports Grill & Arcade, which has sweeping views of San Francisco Bay. Enjoy buffet finger food and drinks (beer, wine, soft drinks) plus arcade games and pool tables. Transportation will be provided. Limited tickets for this event remain for an additional $125 fee. If you want to register for this reception, please stop by the registration desk to reserve your spot.

Wednesday, May 20, 2015

7:30
Coffee

8:00
Chairperson's Remarks
Arne Skerra, Ph.D., Professor, Chief Scientific Officer, XL-protein GmbH, Germany

Keynote Presentations

8:15
Patrick Baeuerle
Development of Bite® Antibody Construct Blinatumomab - The First FDA-Approved Bispecific Antibody
Patrick Baeuerle, Vice President, Research; General Manager, Amgen Research GmbH, Germany

8:45
James A. Wells, Ph.D.
Engineered Proteins for Signaling
Jim Wells, Ph.D., Professor and Chair, Pharmaceutical Chemistry, UCSF

9:15
Mark S. Dennis
Receptor-Mediated Delivery of Bispecific Antibodies into the Primate Brain: Challenges and Safety Findings
Mark Dennis, Ph.D., Principal Scientist, Antibody Engineering, Genentech, Inc.

9:45
Networking Refreshment Break

Overcoming Challenges with Manufacturability

10:15
Integration of Discovery through Manufacture
Amar Parashad, Principle Scientist, Pfizer, Inc

10:45
Transitioning Radioimmunoconjugates from the Laboratory to the Clinic: Applying cGMPs to Translational Imaging Trials
Joseph McCann, Ph.D., General Manager, Radiopharmaceutical Operations, Centre for Probe Development and Commercialization

11:15
Advancing a New Payload Through Early Phase Development: Lessons from Process and Analytical Development
Robert Herbst, Scientist, ImmunoGen, Inc.

11:45
Technology Workshop Presentations

12:15
Lunch on your Own

1:25
Chairperson's Remarks
Mark Pozzo, Associate Research Fellow, Group Leader, Pfizer, Inc

Conjugation Reaction and Characterization Strategies

1:30
Orthogonal Determination of DAR and Conjugation Distribution for a Lysine Conjugated ADC
Jim Mo, Research Fellow, Pfizer, Inc

2:00
Modeling Conjugation Efficiency of Multimeric Proteins Using the Multinomial Distribution
Chris Thompson, Associate Scientist, Purification Sciences, MedImmune

2:30
Use of Automation for Execution of DoE
Stephen Freese, Associate Research Fellow, Pfizer, Inc

3:00
Roundtable Discussions & Networking Refreshment Break

CMC Challenges and Regulatory Tactics

3:30
Title TBD
Fred Jacobsen, Ph.D., Principal Scientist, Genentech, Inc.

4:00
Successful CMC Development and Regulatory Strategies for ADCs
Nathan Ihle, Vice President, CMC Strategy and Management, Seattle Genetics

4:30
ADC Process Development Towards a Liquid Formulation
Chris Borths, Senior Scientist, Amgen

5:00
Close of Conferences